Browsing by Subject "Survival"
Now showing items 21-40 of 42
-
Article
Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group
(2014)Cancer of unknown primary origin (CUP) had a poor prognosis, determined by clinico-histological characteristics, partly due to the lack of insights on its biology. We screened tumour DNA from 87 patients with CUP for CTNNB1 ...
-
Article
Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis
(2005)Background: Interest in the use of preoperative systemic treatment in the management of breast cancer has increased because such neoadjuvant therapy appears to reduce the extent of local surgery required. We compared the ...
-
Article
Neuroendocrine carcinoma of unknown primary: A systematic review of the literature and a comparative study with other neuroendocrine tumors
(2011)Introduction: Neuroendocrine carcinomas of unknown primary (NCUP) represent a specific subset with relatively favorable prognosis. Data on biology, management and outcome of NCUP patients have not been systematically ...
-
Article
No response or survival improvement in small cell lung cancer after sequential chemotherapy with three non-cross resistant drug regimens - a pilot study
(1991)In a pilot phase II study we have treated 25 patients with small cell lung cancer by utilizing 3 non-cross resistant drug regimens given in a sequential fashion in combination with radiotherapy to the primary tumor. VAC ...
-
Article
Non-small cell lung cancer in the young: A retrospective analysis of diagnosis, management and outcome data
(2006)Background: Non-small cell lung cancer (NSCLC) in young patients is uncommon and is thought to constitute a distinct oncological entity with characteristic clinicopathological patterns. Since the reported data are scant ...
-
Article
Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: a randomized study.
(1997)A recent phase II study by our group documented a response rate of 27% with the combination paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 plus carboplatin dosed to a target area under the ...
-
Article
Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: Long-term efficacy results: A Hellenic Cooperative Oncology Group (HeCOG) study
(2005)Background: We compared the combination plus Carboplatin plus paclitaxel, which is considered the treatment of choice for initial chemotherapy of advanced ovarian cancer (AOC) with a regimen combining alternating carboplatin ...
-
Article
Proactive Risk-Based Integrity Assessment of Water Distribution Networks
(2010)Sustainable management of urban water distribution networks should include not only new methods for monitoring, repairing or replacing aging infrastructure, but also (and more importantly) expanded methods for modelling ...
-
Article
-
Article
Prognosis of pregnancy-associated breast cancer: A meta-analysis of 30 studies
(2012)Background: Pregnancy-associated breast cancer (PABC) is relatively rare with considerable controversy regarding its prognosis. Patients & methods: Two of the authors independently performed a literature search with no ...
-
Article
Prognostic factors in glioblastoma patients managed with radiotherapy combined with temozolomide
(2014)Purpose: No consensus on clinicopathologic prognostic factors that predict the outcome of patients with newly diagnosed glioblastoma multiforme (GBM) managed with resection, postoperative radiotherapy (RT) and adjuvant ...
-
Article
Prognostic factors in Greek patients with small cell lung cancer (SCLC). A Hellenic Cooperative Oncology Group study
(2002)Background: Prognostic factors among Greek patients with SCLC were evaluated. Patients and Methods: Data from 516 patients with SCLC treated by the Hellenic Cooperative Oncology Group were analyzed. Multivariate analysis ...
-
Article
Prognostication in cancer of unknown primary (CUP): Development of a prognostic algorithm in 311 cases and review of the literature
(2013)Background: CUP represents a heterogeneous population of patients with systemic malignancy and variable outcomes. Identification of clinical, pathologic and laboratory parameters with prognostic utility could contribute ...
-
Article
Psychiatric manifestations, personality traits and health-related quality of life in cancer of unknown primary site
(2013)Objective Psychiatric manifestations and personality traits are known to influence cancer patients. We aimed to assess psychological distress symptoms, psychosocial factors and health-related quality of life (HRQoL) in ...
-
Article
Randomised trials comparing chemotherapy regimens for advanced non-small cell lung cancer: Biases and evolution over time
(2003)We systematically evaluated the evidence from randomised trials comparing various chemotherapy regimens for advanced non-small cell lung cancer. Across 254 eligible trials (42 661 patients), no regimens were compared in ...
-
Article
Randomized evidence on chemotherapy and hormonal therapy regimens for advanced endometrial cancer: An overview of survival data
(2006)Several chemotherapy and hormonal therapy regimens have been used in advanced endometrial cancer. In this review we have systematically evaluated the available data from randomized trials on survival. We searched MEDLINE, ...
-
Article
The role of chemotherapy in non-small cell lung cancer. A retrospective analysis of 100 patients
(1990)
-
Article
Seismic reliability assessment of urban water networks
(2014)We present a framework for the seismic risk assessment of water supply networks, operating in either normal or abnormal conditions. We propose a methodology for assessing the reliability of water pipe networks combining ...
-
Article
A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: A translational research study of the Hellenic Cooperative Oncology Group (HeCOG)
(2014)Background: Bevacizumab, an antibody neutralizing Vascular Endothelial Growth Factor (VEGF), is licensed for the management of patients with advanced colon cancer. However, tumor biomarkers identifying the molecular tumor ...
-
Article
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: Meta-analysis
(2006)Background: Aromatase inhibitors and inactivators have been extensively tested in patients with advanced breast cancer, but it is unclear whether they offer any survival benefits compared with standard hormonal treatment ...